Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall discussions express strong agreement with the promising results of the adjuvant olaparib study, as evidenced by comments like 'practice-changing' and references to trial data showing improved survival rates. The tone and language, such as 'impressive results' and 'significantly reduces the risk,' convey excitement and recognition of the publication’s potential to influence breast cancer treatment.
Most discussions highlight the positive results and significance of the olaparib study, showing strong support for its findings.
The discussions demonstrate high engagement, with many posts referring to clinical trials, FDA approvals, and potential changes in treatment practices, indicating high interest.
Posts include detailed references to clinical trial outcomes, new therapies, and implications for practice, reflecting deep engagement with the research.
The extensive sharing of trial results, mention of practice-changing implications, and optimism about future applications suggest the publication has a substantial impact on the field.
Chemotherapy sucks, but doctors are making steady progress toward making cancer treatment suck less. https://t.co/EplMlUPRY7 https://t.co/IlQXivFtEK
#breastcancer #TNBC https://t.co/p8SPwss7C0 13/n https://t.co/hb2ugOVsg4
# 4 Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer @NEJM @dradityabardia @stolaney1 @tmprowell @ErikaHamilton9 @DrSGraff https://t.co/RJq7zYPvHo
Now that PARP inhibitors have been proven to benefit BRCA mutated breast cancer patients in the adjuvant setting (rather than just the metastatic), let’s be optimistic that they will be approved in BRCA mutated prostate and pancreatic cancers too! #cancer https://t.co/UBeEQWFMYm
@TumorBoardTues @JenniferLitton @JasmineSukumar @Dr_RShatsky @awolff @jane_meisel @sardesai_sagar @andMORand @MassimoDiMaio75 @MLambouras @melindatelli @IBCradiation @TJH0828 @naborala @MuozMateu @FadwaARahman @emrekocamd @spinmaplered @LeandroJonatad1 @crisonco @adrianakahnmd @MamMa_mimumemo @LauBuisseret @MPishvaian @JohnEbbenMDPhD @NCCN @ASBrS 6/18 #TumorBoardTuesday
Explore how science is transforming cancer treatment through targeted therapies and personalized medicine, improving outcomes for patients with specific genetic mutations.
Olaparib, an oral PARP inhibitor, improves survival in patients with early high-risk HER2-negative breast cancer with BRCA mutations, based on the Phase 3 Olympia Trial involving 1836 patients. It offers a new effective…
This video discusses BRCA 12 genes and their link to malignancy, family history assessment for genetic testing, risk reduction strategies, and systemic therapy considerations for BRCA positive breast cancer, based on…
RT @prarthnavb: @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @YAbdouMD @PTarantinoMD @drteplinsky @ArielleMedford @stolaney1 @nlinmd @dradit…
RT @prarthnavb: @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @YAbdouMD @PTarantinoMD @drteplinsky @ArielleMedford @stolaney1 @nlinmd @dradit…
RT @prarthnavb: @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @YAbdouMD @PTarantinoMD @drteplinsky @ArielleMedford @stolaney1 @nlinmd @dradit…
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @YAbdouMD @PTarantinoMD @drteplinsky @ArielleMedford @stolaney1 @nlinmd @dradityabardia @hoperugo @maryam_lustberg @Dr_RShatsky @ErikaHamilton9 @BCJoyceO @DrGattiMays @laura_huppert @drivorymd @DrSGraff @jane_meisel @JenniferLitton @drsarahsam @IlanaSchlam @hmcarthur 7/13 #TumorBoardTuesday
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer https://t.co/PiIRgV8TkJ
@notshenetworks Hank Green is not a "rage engagement baiter." He does cool science videos on Youtube: https://t.co/MVT3vbP69r.
Was cleaning and stumbled on this video about Chemotherapy. This is pretty rad. #Science #Cancer https://t.co/jx4TmNTgWl
New advancements in treating #cancer. https://t.co/KPSKHh5xIs
@BreastDocUK @macmillancancer @BreastDocUK tells us about: ➡️ advances in genomics: https://t.co/5KPjw6s03s Dedicated @macmillancancer resources on genomics: https://t.co/cTy2GjFqPK #macmillanprimarycareconference23 https://t.co/KNrrFLrLVm
@Agent48189582 @slobodanchudjak 3) "I'd prefer chemo." Right, because you're a fucking moron. Chemo is awful, and comes with enormous risks. https://t.co/TN8UK7qzGV
STEM communication
Chemo Sucks. Science Is Changing That https://t.co/rgmqjgxT3T via @YouTube #scishow
Chemo Sucks. Science Is Changing That https://t.co/tRLwlAZ5Vj via @YouTube
@GGnosticism Even with cancer you gotta maintain that soyface! https://t.co/IeP5YVR3y9
Chemo Sucks. Science Is Changing That https://t.co/8fTOwJiiDT via @YouTube
https://t.co/EH9vhiwtLA Treatments for cancer https://t.co/miL0VDwrRP
https://t.co/vWNo3t76C8
Chemo Sucks. Science Is Changing That https://t.co/sJ141d04i7 via @YouTube
https://t.co/I4ogAUtZDk
Main video:https://t.co/vKd47GZaMH Thanku next remix:https://t.co/Gk2q6lFqAF https://t.co/neqXesFaeL
Chemo Sucks. Science Is Changing That https://t.co/XEiyuNJeif via @YouTube
Chemo Sucks. Science Is Changing That https://t.co/sWj0fVPCtJ via @YouTube
https://t.co/jSHgiWIlAM
https://t.co/eqDldV6jr3
https://t.co/W21oUW7wjE
RT @Andrewemcameron: @ThanksCancer New to chemo? Curious wtf it is doing? Want to know what kind of treatments are just around the corner?…
Chemo Sucks. Science Is Changing That https://t.co/zIhSB8Do29 via @YouTube
RT @SciShow: Chemotherapy sucks, but doctors are making steady progress toward making cancer treatment suck less. https://t.co/EplMlUPRY7 h…
https://t.co/G8H0yAfqVP
Chemo Sucks. Science Is Changing That https://t.co/nvpXAi3NEI via @YouTube
Ome of my favourite science creators. https://t.co/zW75rNMWI8
Chemo Sucks. Science Is Changing That https://t.co/29YCr3hIXN via @YouTube
@ThanksCancer New to chemo? Curious wtf it is doing? Want to know what kind of treatments are just around the corner? This is the video for you. https://t.co/r3V0Yg6FaU
Chemo Sucks. Science Is Changing That https://t.co/1KfLbOI3we via @YouTube
RT @SciShow: Chemotherapy sucks, but doctors are making steady progress toward making cancer treatment suck less. https://t.co/EplMlUPRY7 h…
Where Hank educates us on chemotherapy less than a month after finishing a cycle of chemotherapy. Chemo Sucks. Science Is Changing That https://t.co/87dIgzn0K5 via @YouTube
RT @SciShow: Chemotherapy sucks, but doctors are making steady progress toward making cancer treatment suck less. https://t.co/EplMlUPRY7 h…
RT @SciShow: Chemotherapy sucks, but doctors are making steady progress toward making cancer treatment suck less. https://t.co/EplMlUPRY7 h…
RT @SciShow: Chemotherapy sucks, but doctors are making steady progress toward making cancer treatment suck less. https://t.co/EplMlUPRY7 h…
RT @SciShow: Chemotherapy sucks, but doctors are making steady progress toward making cancer treatment suck less. https://t.co/EplMlUPRY7 h…
RT @SciShow: Chemotherapy sucks, but doctors are making steady progress toward making cancer treatment suck less. https://t.co/EplMlUPRY7 h…
Chemotherapy sucks, but doctors are making steady progress toward making cancer treatment suck less. https://t.co/EplMlUPRY7 https://t.co/IlQXivFtEK
https://t.co/rgoDu8dcw3
Chemo https://t.co/hyILMob24P
RT @marijasullivan: @TumorBoardTues @JenniferLitton @JasmineSukumar @Dr_RShatsky @awolff @jane_meisel @sardesai_sagar @andMORand @MassimoDi…
RT @marijasullivan: @TumorBoardTues @JenniferLitton @JasmineSukumar @Dr_RShatsky @awolff @jane_meisel @sardesai_sagar @andMORand @MassimoDi…
@TumorBoardTues @JenniferLitton @JasmineSukumar @Dr_RShatsky @awolff @jane_meisel @sardesai_sagar @andMORand @MassimoDiMaio75 @MLambouras @melindatelli @IBCradiation @TJH0828 @naborala @MuozMateu @FadwaARahman @emrekocamd @spinmaplered @LeandroJonatad1 @crisonco @adrianakahnmd @MamMa_mimumemo @LauBuisseret @MPishvaian @JohnEbbenMDPhD @NCCN @ASBrS 6/18 #TumorBoardTuesday
RT @quirogad: @TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @…
RT @quirogad: @TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @…
RT @quirogad: @TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @…
RT @quirogad: @TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @…
@TumorBoardTues @jane_meisel @MPishvaian @JohnEbbenMDPhD @JasmineSukumar @DrGattiMays @StoverLab @sardesai_sagar @OncoAlert @MarkRobsonMD @US_FDA @drjennifergao @FDAOncology 14/17 #TumorBoardTuesday
https://t.co/UwXgoWVBOw
@Dr_RShatsky @SyedMAhmedMDPhD https://t.co/CqYDMgfZwE To me 25 % grade 3 side effects is not trivial... https://t.co/CXJxiSAqNL
日本でも保険適応に！ RRSOの対象も再考が必要になるかもしれないですね。 Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM https://t.co/QmmcaeUUp4
RT @paspears88: Plenary Session: #OlympiA clinical trial of adjuvant olaparib for patients with early breast cancer who have inherited muta…
RT @JohnEbbenMDPhD: @HannahAlison20 @ArielleMedford @TumorBoardTues I think you're exactly right @HannahAlison20. I just took a quick look…
RT @JohnEbbenMDPhD: @HannahAlison20 @ArielleMedford @TumorBoardTues I think you're exactly right @HannahAlison20. I just took a quick look…
@HannahAlison20 @ArielleMedford @TumorBoardTues I think you're exactly right @HannahAlison20. I just took a quick look at the study- high risk features, defined as CPS+EG>3. https://t.co/2OASdwgo2r
@toddscarbrough Link to pub: https://t.co/gF1GkdWlYJ
Today's #APaperADay article on recently FDA approved adjuvant olaparib for the treatment of BRCA-mutated, HER2-negative breast cancer. Published in @NEJM, it presents the findings of phase 3, double-blind, RCT with a primary end point of invasive DFS. https://t.co/VIgMdTpDdC
RT @Rndubois: Adjuvant #Olaparib for Patients with #BRCA1- or #BRCA2-Mutated #Breast #Cancer extends survival free of invasive or distant d…
Adjuvant #Olaparib for Patients with #BRCA1- or #BRCA2-Mutated #Breast #Cancer extends survival free of invasive or distant disease | NEJM https://t.co/cXdS7y4LyA
RT @VivekSubbiah: # 4 Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer @NEJM @dradityabardia @stolaney1 @tmprowell…
RT @VivekSubbiah: # 4 Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer @NEJM @dradityabardia @stolaney1 @tmprowell…
RT @VivekSubbiah: # 4 Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer @NEJM @dradityabardia @stolaney1 @tmprowell…
# 4 Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer @NEJM @dradityabardia @stolaney1 @tmprowell @ErikaHamilton9 @DrSGraff https://t.co/RJq7zYPvHo
Eg. breast cancers lacking BRCA are very sensitive to inhibiting the protein PARP which acts in several DNA repair pathways https://t.co/qL4IH4tUVY 4/n.
#breastcancer #TNBC https://t.co/p8SPwss7C0 13/n https://t.co/hb2ugOVsg4
RT @T_Allen1998: @FamilialGenes @bccww @abcdiagnosis @BreastCancerNow @CRUKresearch Here’s the abstract. https://t.co/2cDzoMTxVH
RT @T_Allen1998: @FamilialGenes @bccww @abcdiagnosis @BreastCancerNow @CRUKresearch Here’s the abstract. https://t.co/2cDzoMTxVH
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM https://t.co/srUwMKFBoa
@FamilialGenes @bccww @abcdiagnosis @BreastCancerNow @CRUKresearch Here’s the abstract. https://t.co/2cDzoMTxVH
4/ Dr. Bhamidipati presented the results of the OlympiA trial, which explored the use of adjuvant olaparib
RT @DrSGraff:
RT @DrSGraff:
RT @DrSGraff:
RT @DrSGraff:
RT @DrSGraff:
RT @DrSGraff:
RT @DrBonillaOnc: @oncologician @prat_aleix @DrSGraff @stolaney1 @matteolambe @pashtoonkasi @ChristianRolfo https://t.co/zWoxQRktac
RT @DrBonillaOnc: @oncologician @prat_aleix @DrSGraff @stolaney1 @matteolambe @pashtoonkasi @ChristianRolfo https://t.co/zWoxQRktac
@oncologician @prat_aleix @DrSGraff @stolaney1 @matteolambe @pashtoonkasi @ChristianRolfo https://t.co/zWoxQRktac
@oncologician @prat_aleix @DrSGraff @stolaney1 @matteolambe @pashtoonkasi @ChristianRolfo https://t.co/zWoxQRktac
RT @drkellyphillips: Practice- changing. Olaparib ⬇️ breast cancer recurrence in BRCA1/2 carriers by 42%! It’s time to advocate for BRCA1/2…
RT @matteolambe: Expected to be presented at the #ASCO21 plenary session, #OlympiA trial is already published in @NEJM: impressive results…
Patients with high-risk, HER2 -ve early breast cancer, BRCA1/BRCA2 pathogenic/likely pathogenic variants, olaparib after local treatment & neoadjuvant/adjuvant chemotherapy was associated with longer survival free of invasive or distant disease: https://t.co/VqSqhmJAhJ https://t.co/ju9CZTwAYJ
RT @Latinamd: Just in time for #ASCO21 Plenary Session Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | via @NEJ…
Adjuvant Olaparib for Patients BRCA1 or BRCA2 Mutated Breast Cancer; a positive trial for this patient type to consider adjuvant therapy that would work better than placebo https://t.co/YWEz949yaj https://t.co/wti30SSA5g
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM https://t.co/ABt8YNjCl0
2021/6/24 出版分 twitterでバズった論文 全分野 Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer https://t.co/N3kQu9BNjc 464tweets
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM https://t.co/F3VsmtGMjn
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM https://t.co/gTDMpofCNN
#BestStudyoftheDay: Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer https://t.co/BeVPlJ0LL9 – New England Journal of Medicine - #senology #breast #cancer #oncology
A major study has shown that giving women the drug olaparib following chemo therapy significantly reduces the risk of inherited #breastcancer returning or spreading. #her2negative #brca1 #brca2 https://t.co/AWTMlGh0Ng
RT @matteolambe: Expected to be presented at the #ASCO21 plenary session, #OlympiA trial is already published in @NEJM: impressive results…
BREAST: adjuvant treatment with the PARP inhibitor olaparib improved survival and reduced disease recurrence for localised high risk HER2-negative BRCA1/2 mutant disease. https://t.co/JBJs8DlD1J
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer https://t.co/4A78bhONy2
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer https://t.co/XsTCVWFnTI @ABSGBI @brca
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM https://t.co/PHKJa9kpge
RT @stolaney1: Adjuvant olaparib x 1yr improves iDFS in pts with high risk breast cancer and gBRCAm!
RT @inheritedcancer: For more information view the article at
New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation–associated early breast cancer - https://t.co/2QB3EzCcWU @NEJM
Now that PARP inhibitors have been proven to benefit BRCA mutated breast cancer patients in the adjuvant setting (rather than just the metastatic), let’s be optimistic that they will be approved in BRCA mutated prostate and pancreatic cancers too! #cancer https://t.co/UBeEQWFMYm
For more information view the article at
2021年06月10日【アストラゼネカ｜日】『リムパーザ、生殖細胞系列BRCA遺伝子変異陽性高リスクの早期乳がん患者さんの術後補助療法における第Ⅲ相OlympiA試験で、がん再発リスクを42%低減』が公開されています 英本社発表抄訳 https://t.co/5MT6BEFh4N https://t.co/QLsDRFi52W
Exciting new article showing the importance of genetic testing in thr management of breast cancer https://t.co/uUZusoOfsl
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM https://t.co/z41zwj8n4D
[#ASCO2021] Résultats de l'étude OlympiA publiés dans N Engl J Med (https://t.co/CkK6YzzQmL , https://t.co/jiq5eZ9cj6). Plus d'infos sur les inhibiteurs de PARP dans notre prochaine Newsletter Onco. Rejoignez-nous sur https://t.co/H0zQkK34D6
Adjuvant #Olaparib for Patients w/ #BRCA1- or #BRCA2-#MutatedBreastCancer Andrew N.J. Tutt, M.B., Ch.B., Ph.D., et al. Guy’s Hospital Cancer Centre https://t.co/GmpqYZndwO @NEJM [FREE] https://t.co/QNWrdFQIrH
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer https://t.co/znN5THEy32 #hvhebron #onco @NEJM
En pac c/CA mama temprano HER2- alto riesgo y BRCA1 o BRCA2, olaparib adyuvante luego de TTO local y Qt neoadyuvante o adyuvante asoc c/supervivencia libre de enfermedad invasiva o distante más prolongada https://t.co/aNE4kymOSZ
RT @drkellyphillips: Practice- changing. Olaparib ⬇️ breast cancer recurrence in BRCA1/2 carriers by 42%! It’s time to advocate for BRCA1/2…
RT @Latinamd: Just in time for #ASCO21 Plenary Session Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | via @NEJ…
RT @tmprowell: #ASCO21 #bcsm OlympiA Trial. Dr. Andrew Tutt et al. Plenary Session Sun 6/6/2021 1pm EDT (LBA1: https://t.co/fn3x8ibKEv) & o…
RT @stveep: Big news for PARP inhibitors in breast cancer today - OlympiA trial showing benefit of one years' adjuvant olaparib treatment i…
RT @stveep: Big news for PARP inhibitors in breast cancer today - OlympiA trial showing benefit of one years' adjuvant olaparib treatment i…
RT @stveep: Big news for PARP inhibitors in breast cancer today - OlympiA trial showing benefit of one years' adjuvant olaparib treatment i…
RT @stveep: Big news for PARP inhibitors in breast cancer today - OlympiA trial showing benefit of one years' adjuvant olaparib treatment i…
RT @stveep: Big news for PARP inhibitors in breast cancer today - OlympiA trial showing benefit of one years' adjuvant olaparib treatment i…
Trending on PubMed: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. https://t.co/zEeAqCjkDP
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer reduces invasive disease by 9% at 3 years. NEJM https://t.co/zMXGAPvq6P #bcsm
@renata_bonadio @OncoAlert 1)I thought the DFS for BRCA breast for olaparib (85.9% vs 77.1%) was significant p<0.001. Else not "prac chging" https://t.co/TG0cBBVBAY 2) Is it translated by specialty... or disease site? 3) There is no Susan G Komen foundation, "Race for the Cure" etc in lung cancer (sadly)
RT @tmprowell: #ASCO21 #bcsm OlympiA Trial. Dr. Andrew Tutt et al. Plenary Session Sun 6/6/2021 1pm EDT (LBA1: https://t.co/fn3x8ibKEv) & o…
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM https://t.co/ZyskXwWnLu
今年のASCOのLateBraking演題のやつかな。後で読む。 Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM https://t.co/WQuSs0TUTz
RT @paspears88: Plenary Session: #OlympiA clinical trial of adjuvant olaparib for patients with early breast cancer who have inherited muta…
RT @paspears88: Plenary Session: #OlympiA clinical trial of adjuvant olaparib for patients with early breast cancer who have inherited muta…
RT @drkellyphillips: Practice- changing. Olaparib ⬇️ breast cancer recurrence in BRCA1/2 carriers by 42%! It’s time to advocate for BRCA1/2…
RT @drkellyphillips: Practice- changing. Olaparib ⬇️ breast cancer recurrence in BRCA1/2 carriers by 42%! It’s time to advocate for BRCA1/2…
RT @matteolambe: Expected to be presented at the #ASCO21 plenary session, #OlympiA trial is already published in @NEJM: impressive results…
One year of olaparib (brand name Lynparza) in early stage, HER2-, BRCA mutated breast cancer... "The Phase III clinical trial showed that taking olaparib tablets twice daily for a year reduced br ca recurrence by 42%." https://t.co/oZa0Fdh2jI https://t.co/TG0cBBVBAY
@MammaMiaMagazin Das hätte ich auch weit oben erwähnt! https://t.co/J7D8Zisikd
RT @paspears88: Plenary Session: #OlympiA clinical trial of adjuvant olaparib for patients with early breast cancer who have inherited muta…
RT @paspears88: Plenary Session: #OlympiA clinical trial of adjuvant olaparib for patients with early breast cancer who have inherited muta…
RT @paspears88: Plenary Session: #OlympiA clinical trial of adjuvant olaparib for patients with early breast cancer who have inherited muta…
RT @paspears88: Plenary Session: #OlympiA clinical trial of adjuvant olaparib for patients with early breast cancer who have inherited muta…
For more information on this Phase III Trial: https://t.co/JTXQIXbAod To read more about BRCA gene and the inherited risk of breast cancer check out our blog: https://t.co/O3tc1FuASl
RT @paspears88: Plenary Session: #OlympiA clinical trial of adjuvant olaparib for patients with early breast cancer who have inherited muta…
RT @paspears88: Plenary Session: #OlympiA clinical trial of adjuvant olaparib for patients with early breast cancer who have inherited muta…
RT @paspears88: Plenary Session: #OlympiA clinical trial of adjuvant olaparib for patients with early breast cancer who have inherited muta…
RT @kevinjmonahan: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer https://t.co/qnq6BpqWFi @NEJM
【RCT】HER-2陰性、BRCA1/BRCA2生殖細胞系列変異陽性または変異陽性の可能性および臨床病理学的ハイリスク因子があり、局所治療および術前または術後補助化学療法を受けた乳癌患者へのオラパリブ投与は、プラセボ投与と比較して、3年無浸潤疾患生存率を改善させた。 #ペ読 https://t.co/wy78c3HiT1
RT @PaperbirdsO: New article: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer https://t.co/k4nYWFuQKu #breastcanc…
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer https://t.co/oPGqzSPxbH
RT @PaperbirdsO: New article: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer https://t.co/k4nYWFuQKu #breastcanc…
New article: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer https://t.co/k4nYWFuQKu #breastcancer #oncology https://t.co/JvYS3ovQW3
AM
LS